U.S. FDA

arrow back backwards u-turn turn around reverse

Fierce Pharma

Hims quits on obesity pill after legal, regulatory heat

Hims has quickly retreated from its launch of a compounded obesity pill after facing mounting pressure from the FDA and Novo Nordisk.

Fraiser Kansteiner Feb 9, 2026 10:24am

Makary

Fierce Pharma

FDA commissioner pledges crackdown on compounding practices

Feb 6, 2026 9:59am